New Associate Dean For Translational Research Named At Columbia University Medical Center

September 20, 2004

Dr. Eric A. Rose Will Lead the Integration of Basic Science with Clinical Research To Ultimately Develop New Technologies and Therapies

NEW YORK, NY (SEPT. 20, 2004) -- Columbia University Medical Center has announced the appointment of Eric A. Rose, M.D. as Associate Dean for Translational Research. This is a newly created position at Columbia, which is one of the first medical institutions to create such a role. Dr. Rose is also chairman of the Department of Surgery, the Morris and Rose Milstein, and Johnson and Johnson Professor of Surgery at Columbia University College of Physicians & Surgeons.

Translational research bridges scientific discovery and clinical delivery, with the ultimate goal to successfully introduce novel diagnostic, therapeutic and preventive approaches to illness. One of the primary benefits of translational research is enabling non-profit medical institutions, such as Columbia, to retain intellectual ownership over new technologies and therapies developed by its researchers.

“I am honored to be appointed to this new role, which is a measure of Columbia’s leadership in medical innovation,” said Dr. Rose. “I will be working to expand the classic definition of translational research – transferring laboratory research into improvements in patient care – to include the creation of new communication channels that will encourage medical professionals to take observations from patients back to the laboratory for clinical modeling.”

As a practicing cardiovascular surgeon and clinical researcher, Dr. Rose is a leader in translational research. For example, he spent years working to develop left ventricular assist devices (LVADs) to lengthen and improve the lives of end stage congestive heart failure patients, based on clinical observations about their high mortality risk. Dr. Rose led the landmark clinical trial that helped demonstrate the efficacy of LVADs for these critically ill patients for whom heart transplant was deemed not an option. The devices have since been approved by the U.S. Food and Drug Administration and Medicare/Medicaid Services and are now available as a therapeutic option to the more than 100,000 people in the United States suffering from this condition.

“Advances in Translational Research” – Symposium Oct. 12, 2004 Next month Dr. Rose will co-chair a research symposium, “Advances in Translational Research,” on Oct. 12, 2004, 7 a.m. – 5:30 p.m. in New York City. The symposium aims to bring together researchers and clinicians with the biotech and pharmaceutical industries, and will provide both classic and non-classic examples of translational research in the fields of cardiovascular and oncology. Details will be distributed shortly under separate communication.


*Located in New York City, Columbia University Medical Center provides international leadership in basic and clinical research, medical education, and health care. The medical center includes the dedicated work of many physicians, scientists, and other health professionals at the College of Physicians & Surgeons, the School of Dental & Oral Surgery, the School of Nursing, the Mailman School of Public Health, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. The pioneering tradition of Columbia University health scientists, who have achieved some of the 20th century's most significant medical breakthroughs, continues today.


Drug Administration, Mailman School, New York City, Physicians Surgeons